Enhancement of paclitaxel and carboplatin therapies byCCL2 blockade in ovarian cancers

Molecular Oncology

Volumn 8, Issue 7, 2014, Pages 1231-1239

  Moisan, Francois ^a,c   Francisco, Edgar B ^a   Brozovic, Anamaria ^a   Duran, George E ^a   Wang, Yan C ^a   Chaturvedi, Shalini ^b   Seetharam, Shobha ^b   Snyder, Linda A ^b   Doshi, Parul ^b   Sikic, Branimir I ^a  

^a STANFORD UNIVERSITY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Bordeaux Institute of Oncology   (France)

Author keywords

Carboplatin; CCL2; CCR2; EMT; Paclitaxel; Resistance; TAMs

Indexed keywords

C 1142; CARBOPLATIN; CARLUMAB; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; PACLITAXEL; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; NUDE MOUSE; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CHEMOKINE CCL2; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; OVARY; PACLITAXEL;

EID: 84908540608     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.016     Document Type: Article

References (23)

1. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. New Engl. J. Med. 2006, 354:610-621.
2. Chen K.G., Sikic B.I. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:1863-1869.
3. Creusot R.J., Yaghoubi S.S., Kodama K., Dang D.N., Dang V.H., Breckpot K., Thielemans K., Gambhir S.S., Fathman C.G. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin. Immunol. 2008 May, 127(2):176-187.
4. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J.Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 2009, 29:313-326.
5. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 1999, 5:3445-3453.
6. Fetterly G.J., Aras U., Meholick P.D., Takimoto C., Seetharam S., McIntosh T., de Bono J.S., Sandhu S.K., Tolcher A., Davis H.M., Zhou H., Puchalski T.A. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J.Clin. Pharmacol. 2013, 53:1020-1027.
7. Fridlender Z.G., Kapoor V., Buchlis G., Cheng G., Sun J., Wang L.-C.S., Singhal S., Snyder L.A., Albelda S.M. Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am. J. Respir. Cell Mol. Biol. 2011, 44:230-237.
8. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
9. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31:277-283.
10. Loberg R.D., Day L.L., Harwood J., Ying C., St John L.N., Giles R., Neeley C.K., Pienta K.J. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (New York, N.Y.) 2006, 8:578-586.
11. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., Wojno K., Snyder L.A., Yan L., Pienta K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression invivo. Cancer Res. 2007, 67:9417-9424.
12. Low-Marchelli J.M., Ardi V.C., Vizcarra E.A., van Rooijen N., Quigley J.P., Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 2013, 73:662-671.
13. Nam J.-S., Kang M.-J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., Jordan V.C., Hirohashi S., Wakefield L.M. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 2006, 66:7176-7184.
14. Obmolova G., Teplyakov A., Malia T.J., Grygiel T.L.R., Sweet R., Snyder L.A., Gilliland G.L. Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888. Mol. Immunol. 2012, 51:227-233.
15. Pienta K.J., Machiels J.-P., Schrijvers D., Alekseev B., Shkolnik M., Crabb S.J., Li S., Seetharam S., Puchalski T.A., Takimoto C., Elsayed Y., Dawkins F., de Bono J.S. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investig. New Drugs 2012, 2.
16. Qian D.Z., Rademacher B.L.S., Pittsenbarger J., Huang C.-Y., Myrthue A., Higano C.S., Garzotto M., Nelson P.S., Beer T.M. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 2010, 70:433-442.
17. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
18. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
19. Sandhu S.K., Papadopoulos K., Fong P.C., Patnaik A., Messiou C., Olmos D., Wang G., Tromp B.J., Puchalski T.A., Balkwill F., Berns B., Seetharam S., de Bono J.S., Tolcher A.W. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 2013, 71:1041-1050.
20. Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N., Longacre T.A., Botstein D., Brown P.O., Sikic B.I. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 2003, 14:4376-4386.
21. Tsuyada A., Chow A., Wu J., Somlo G., Chu P., Loera S., Luu T., Li X., Wu X., Ye W., Chen S., Zhou W., Yu Y., Wang Y.-Z., Ren X., Li H., Scherle P., Kuroki Y., Wang S.E. CCL2 mediates crosstalk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012, 2768-2779.
22. Vergara D., Merlot B., Lucot J.-P., Collinet P., Vinatier D., Fournier I., Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010, 291:59-66.
23. Zhang J., Patel L., Pienta K.J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010, 21:41-48.